Epithelial ovarian cancer (EOC) remains the leading cause of gynecologic cancer death in the United States, with most women diagnosed with advanced-stage disease. The peritoneal cavity is a primary source of spread of this disease at initial presentation and failure at the time of recurrence. While the standard of care remains surgical cytoreduction with platinum and taxane chemotherapy, ovarian cancer’s natural history and disease distribution lend itself toward intraperitoneal chemotherapy. There are data in animal models that demonstrate improved distribution of drug, higher intra-tumoral concentrations, and increased DNA adduct formation when platinum drugs are administered directly into the peritoneal cavity (IP) as compared with intravenous administration (IV). Importantly, there are a number of landmark clinical trials that have established IP chemotherapy as superior to IV chemotherapy in women with newly diagnosed advance EOC with statistically significant improvement in both progression-free survival and overall survival. Despite clearly improved outcomes, a minority of women with EOC are receiving IP therapy.